Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Subtle protein misfolding often evades standard gel electrophoresis but ruins biological training data. By including chemical analogs of molecular chaperones like lumacaftor in the screening library, unexpected binding hits instantly flag improperly folded protein batches so they can be discarded before polluting ML datasets.

Related Insights

Public datasets primarily show successful protein interactions, starving AI models of crucial "negative data"—plausible but incorrect interactions. A-Alpha Bio finds that providing this data on what fails is just as important for training predictive and generalizable models.

While de-duplicating protein databases helps learn diverse structures, subtle variations in similar sequences are essential for learning function, as a single mutation can be catastrophic. This justifies training models on massive, unclustered datasets to capture fine-grained functional determinants.

To break the data bottleneck in AI protein engineering, companies now generate massive synthetic datasets. By creating novel "synthetic epitopes" and measuring their binding, they can produce thousands of validated positive and negative training examples in a single experiment, massively accelerating model development.

Traditional drug discovery groups run DNA encoded libraries against isolated, difficult targets in hope of a single hit, missing systematic library quirks. Screening every library across hundreds of targets surfaces batch-to-batch manufacturing variations, chemical motifs, and assay failure modes that single screens never detect.

Traditional protein engineering relies on slow, serial single-residue substitutions in wet labs to preserve stability. Machine learning models trained on evolutionary datasets can predict multiple coordinated amino acid changes simultaneously, cutting optimization rounds down from dozens to a handful.

While optimizing for a primary quality attribute like glycan profile, always measure secondary metrics such as aggregation and charge variance. The incremental cost is minimal since the cultures are already running, but the data can reveal critical, unforeseen effects that influence which candidates you advance.

Instead of relying on gene co-expression data, a technique using cell permeabilization and proximity biotinylation can identify the specific cellular machinery physically interacting with and supporting a biologic's production. This reveals critical chaperones and support proteins needed for high titers, moving beyond correlation to causation.

When all pharma companies use similar AI models on similar data, competitive moats vanish. The next edge will come from creating superior training data. This means moving beyond raw data to datasets enriched with physical insights, such as a database of 'complexity hotspots' for all known proteins, teaching AI the underlying dynamics.

Standard co-folding models struggle with induced proximity because public databases like the PDB lack sufficient training data for multi-protein complexes. Because dynamic multi-protein complexes take on endless conformations, standard AI models become overconfident and inaccurate. To solve this, Protai generates proprietary structural proteomics data that maps physical distances and conformations, enabling accurate modeling of complexes that can be targeted by molecular glues and PROTACs.

Generative AI alone designs proteins that look correct on paper but often fail in the lab. DenovAI adds a physics layer to simulate molecular dynamics—the "jiggling and wiggling"—which weeds out false positives by modeling how proteins actually interact in the real world.